MCT2D Clinician Decision Aid: SGLT-2 Inhibitor / GLP-1 RA for Type 2 Diabetes

Why this aid?
SGLT2-inhibitors and GLP-1 receptor agonists are two newer classes of medications for diabetes that reduce hyperglycemia, reduce endogenous insulin production, and improve cardiovascular and renal outcomes, weight loss, and mortality in Type 2 Diabetes.
This aid is meant to be used alongside your own clinical judgment and prescribing information to guide individualization of diabetes treatment.
Tags:
For ProvidersNon-videoPDFCreated-By-MCT2DPoint-of-care